Are your patients getting the proper level of anticoagulation?
Posted: April 28, 2023
It’s Not Just Support. It’s Solutions.
Measuring Warfarin in Patients with a Lupus Anticoagulant
At the recent HTRS 2023 Scientific Symposium, a lively discussion in a Plenary Session was presented titled, “Do We Dare to DOAC?” in which presenters debated the use of DOACs in patients with antiphospholipid antibody syndrome (aPS).
For an in-depth review, read our April Clot Club post, “Should Direct Oral Anticoagulants (DOAC) be Used in Individuals with Antiphospholipid Syndrome (aPS) vs Long Term Warfarin Treatment?”
The topic brings up the questions:
- Do LA/aPS patients always get the best anticoagulation treatments?
- What are the options for monitoring a patient with the presence of a strong LA inhibitor, where INRs might be unreliable?
- What test can measure the effect of warfarin to help ensure the patient is in therapeutic range?
The chromogenic FX assay can be used here to measure % FX. Chromogenic FX activity levels have shown utility for monitoring warfarin therapy in patients where INR is unreliable, such as in aPS (Rosborough & Shepherd, 2004).
The DiaPharma Factor X Kit is accessible, FDA cleared, and offered by reference labs across the U.S.
Visit diapharma.com to learn more.
Monitoring warfarin is a delicate balance
Reference: Rosborough T.K., Shepherd M.F. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy. 2004;24(7):838–842.
View our full portfolio of hemostasis and thrombosis assays at diapharma.com.
It’s Not Just Support. It’s Solutions.
Over 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-01-00014Rev01